Company: LCTX
Filing Date: 2025-03-10
Form Type: 10-K
Source: 0000950170-25-036309
Chunk: 215

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-03-10
Form: 10-K
Item: Item 1B
Chunk 215
---
, 2017, between Registrant and HBL-Hadasit Bio-Holdings Ltd.
     
    10.3
     
    10-Q
     
    August 9, 2017
     
    001-12830

    10.12†
     
    Share Purchase and Transfer Agreement dated June 16, 2017, by and among Registrant and HBL-Hadasit Bio-Holdings Ltd. and Cell Cure Neurosciences Ltd.
     
    10.4
     
    10-Q
     
    August 9, 2017
     
    001-12830

    10.13†
     
    Non-exclusive License Agreement dated October 7, 2013 between WARF and Asterias
     
    10.5
     
    Asterias 10-Q
     
    November 12, 2013
     
    000-55046

    10.14
     
    Form of Securities Purchase Agreement dated November 19, 2024, between Lineage Cell Therapeutics, Inc. and the purchaser parties thereto
     
    10.1
     
    8-K
     
    November 20, 2024
     
    001-12830

    10.15
     
    Form of Securities Purchase Agreement dated November 19, 2024, between Lineage Cell Therapeutics, Inc. and Broadwood Partners, L.P.
     
    10.2
     
    8-K
     
    November 20, 2024
     
    001-12830

    10.16††
     
    Collaboration and License Agreement dated December 17, 2021, between F. Hoffmann-La Roche Ltd, Genentech, Inc., Cell Cure Neurosciences Ltd., and Registrant
     
    10.13
     
    10-K
     
    March 10, 2022
     
    001-12830

    19.01*
     
    Insider Trading Policy effective June 11, 2024

    OTHER EXHIBITS

    21.01*
     
    List of Subsidiaries of the Registrant

    23.01*
     
    Consent of Moss Adams LLP

    23.02*
     
    Consent of WithumSmith+Brown, PC

    31.01*
     
    Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a)